- Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trialLi, Ning; Zhu, Jianqing; Yin, Rutie; Wang, Jing; Pan, Lingya; Kong, Beihua; Zheng, Hong; Liu, Jihong; Wu, Xiaohua; Wang, Li; Huang, Yi; Wang, Ke; Zou, Dongling; Zhao, Hongqin; Wang, Chunyan; Lu, Weiguo; Lin, An; Lou, Ge; Li, Guiling; Qu, Pengpeng; Yang, Hongying; Zhen, Xiaoa; Hang, Wenzhao; Hou, Jianmei; Banerjee, Ashish; Wu, Lingying
- Efficacy and safety of senaparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer (FLAMES study): A randomized, double-blind, placebocontrolled, phase III trialWu, X.; Liu, J.; Wang, X.; Wang, J.; Wang, L.; Zhu, J.; Kong, B.; Fei, J.; Tang, Y.; Xia, B.; Liang, Z.; Wang, K.; Lin, Z.; Huang, Y.; Zheng, H.; Lin, A.; Jiang, K.; Wang, W.; Wang, X.; Lou, G.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
- Impact of dose modifications due to treatment-emergent adverse events (TEAEs) on the efficacy of niraparib maintenance treatment with an individualized starting dose in patients (Pts) with newly diagnosed advanced ovarian cancer (aOC)Zhu, Jianqing; Wu, Lingying; Yin, Rutie; Wang, Jing; Pan, Lingya; Kong, Beihua; Zheng, Hong; Liu, Jilong; Wu, Xiaohua; Wang, Li; Huang, Yi; Wang, Ke; Zou, Dongling; Zhao, Hongqin; Wang, Chunyan; Lu, Weiguo; Lin, An; Lou, Ge; Li, Guiling; Qu, Pengpeng; Yang, Hongying; Zhang, Yu; Zhen, Xiaoa; Hang, Wenzhao; Hou, Jianmei
会议论文
Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial
21被引4阅读
